News

France-Presse: Medicago Announces Production of a Viable Vaccine Candidate for COVID-19

 Medicago is also using its technology platform to develop antibodies against SARS-CoV-2 in collaboration with the Laval University’s Infectious Disease Research Centre headed by Dr. Gary Kobinger, who helped develop a vaccine and treatment for Ebola. These SARS-CoV-2 antibodies could potentially be used to treat people infected by the virus. This research is being funded, in part, by the Canadian Institutes for Health Research (CIHR).

Medicago is a leader in plant-based technology, having previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

“The pace of our initial progress in COVID-19 is attributable to the capability of our plant-based platform, which is able to produce vaccine and antibody solutions to counteract this global public health threat. The ability to produce a candidate vaccine within 20 days after obtaining the gene is a critical differentiator for our proven technology. This technology enables scale-up at unprecedented speed to potentially combat COVID-19,” said Dr. Bruce Clark, CEO of Medicago.

Dr. Gary Kobinger, Professor in the Department of Microbiology and Infectious Diseases and the Director of the Infectious Disease Research Centre at Laval University, said “The collaborative efforts established between the research team at Laval University and Medicago have been very successful in developing unique antibodies against infectious diseases such as RSV and HMPV, and that experience gives us confidence for successful identification of therapeutic antibodies against SARS-CoV-2.”

Medicago’s first product, a seasonal recombinant quadrivalent VLP vaccine for active immunization against influenza, is currently under review by Health Canada following the completion of a robust safety and efficacy clinical program involving over 25,000 patients.

https://www.afp.com 

Fiți la curent cu ultimele noutăți. Urmărește TIMPUL pe Google News și Telegram!


Leave a Reply

Your email address will not be published. Required fields are marked *

babasının taş gibi bir kadını bulup evlenmeye karar vermesi porno ve onu bir de kendi yaşadıkları eve getirmesi sonucunda mobil porno hayalini kurduğu seksi kadının üvey annesi gibi sex hikayeleri olduğunu fark eden genç adam seks tecrübesinin ve üst sex izle seviye olduğu dışarıdan bakıldığında çok net şekilde porno seyret belli olan üvey annesini hayal edip 31 çekerek düşlerken porno izle odanın oradan geçen mature üvey oğlunu görür Odaya hd porno gelip sikini kimin için kaldırdığını soran üvey annesiyle porno farkında olmadan yakınlaşan genç adam boşalmak mobil porno izle için olgun bir kadının hayallerini kurduğunu söyleyince mature porno izle sikini eline alıp amına sokmadan çıplak şekilde üzerine çıktı